The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Victoza offers a second option in these cases, he added. Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

2024 Healthcare & Pharmaceuticalscategory US FDA approves Hikma's generic version of Novo's diabetes drug Victoza December 23, 2024 Healthcare & Pharmaceuticalscategory US FDA revokes ...